(NASDAQ: PRTA) Prothena Public Co's forecast annual revenue growth rate of 79.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.3%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.86%.
Prothena Public Co's revenue in 2025 is $11,786,000.On average, 9 Wall Street analysts forecast PRTA's revenue for 2025 to be $607,363,687, with the lowest PRTA revenue forecast at $507,132,260, and the highest PRTA revenue forecast at $847,822,217. On average, 9 Wall Street analysts forecast PRTA's revenue for 2026 to be $5,582,169,133, with the lowest PRTA revenue forecast at $5,275,338,236, and the highest PRTA revenue forecast at $5,934,755,516.
In 2027, PRTA is forecast to generate $1,866,823,776 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $5,652,148,110.